Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15494112 | 1.00 | PEPD (0.45) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL17827147 | 1.00 | PEPD (0.45) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL21207444 | 1.00 | PEPD (0.45) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL14340647 | 0.95 | PEPD (0.41) | PEPDMEN1BLMKMT2A | |
| SCHEMBL12942860 | 0.95 | PEPD (0.41) | PEPDMEN1BLMKMT2A | |
| SCHEMBL15494108 | 0.95 | PEPD (0.41) | PEPDMEN1BLMKMT2A | |
| SCHEMBL3148957 | 0.86 | — | — | |
| SCHEMBL2816900 | 0.85 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL30922208 | 0.84 | PEPD (0.40) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL29282878 | 0.84 | PEPD (0.40) | PEPDMEN1BLMKMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220715-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284621-A1 | CANNABINOIDS AND USES THEREOF | CNR2, CNR1, FAAH | PEPD 2988/4885MEN1 2697/4885BLM 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.